Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage

被引:187
作者
Roviezzo, F
Tsigkos, S
Kotanidou, A
Bucci, M
Brancaleone, V
Cirino, G
Papapetropoulos, A
机构
[1] Univ Athens, George P Livanos Marianthi Simou Labs, Evangelismos Hosp, Dept Crit Care & Pulm Serv, Athens, Greece
[2] Univ Patras, Sch Pharm, Mol Pharmacol Lab, Patras, Greece
[3] Univ Naples Federico II, Fac Pharm, Dept Expt Pharmacol, Naples, Italy
关键词
D O I
10.1124/jpet.105.086553
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Angiopoietins (Angs) are endothelium-selective ligands that exert most of their actions through the Tie-2 receptor. It is widely accepted that Ang-1 promotes the structural integrity of blood vessels and exhibits anti-inflammatory properties. In contrast, the role of Ang-2 remains less clear because it has been shown to behave as a Tie-2 agonist or antagonist under different experimental conditions. To define the role of Ang-2 in acute inflammation, we studied the effects of recombinant Ang-2 administration in vivo. We show herein that Ang-2, but not Ang-1, induces edema formation in the mouse paw in a dose-dependent manner; the edema seems to be fast-peaking (maximum at 30 min) and resolves within 4 h. The effect of Ang-2 is blocked by the coadministration with a soluble form of the Tie-2 receptor or Ang-1. NO and prostaglandin E-2 levels in mouse paw following the injection of Ang-2 remained unaltered, suggesting that the action of Ang-2 does not involve these mediators. In addition, Ang-2 exerted a weak stimulatory effect on leukocyte migration in the mouse paw. Similarly, Ang-2 injected into the mouse air pouch produced only a modest effect on cell extravasation that peaked at 30 min. However, when cell migration was elicited using zymosan, Ang-2 significantly inhibited leukocyte migration. We conclude that Ang-2 by itself stimulates the extravasation of cell-poor fluid, but in the presence of ongoing inflammation it reduces cellular infiltration in tissues.
引用
收藏
页码:738 / 744
页数:7
相关论文
共 36 条
[1]   Angiogenic actions of angiopoietin-1 require endothelium-derived nitric oxide [J].
Babaei, S ;
Teichert-Kuliszewska, K ;
Zhang, QW ;
Jones, N ;
Dumont, DJ ;
Stewart, DJ .
AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (06) :1927-1936
[2]   Regulation of vascular permeability by vascular endothelial growth factors [J].
Bates, DO ;
Harper, SJ .
VASCULAR PHARMACOLOGY, 2002, 39 (4-5) :225-237
[3]   Endothelial nitric oxide synthase activation is critical for vascular leakage during acute inflammation in vivo [J].
Bucci, M ;
Roviezzo, F ;
Posadas, I ;
Yu, J ;
Parente, L ;
Sessa, WC ;
Ignarro, LJ ;
Cirino, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (03) :904-908
[4]   HSP90 and Akt modulate Ang-1-induced angiogenesis via NO in coronary artery endothelium [J].
Chen, JX ;
Lawrence, ML ;
Cunningham, G ;
Christman, BW ;
Meyrick, B .
JOURNAL OF APPLIED PHYSIOLOGY, 2004, 96 (02) :612-620
[5]   Isolation of Angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning [J].
Davis, S ;
Aldrich, TH ;
Jones, PF ;
Acheson, A ;
Compton, DL ;
Jain, V ;
Ryan, TE ;
Bruno, J ;
Radziejewski, C ;
Maisonpierre, PC ;
Yancopoulos, GD .
CELL, 1996, 87 (07) :1161-1169
[6]  
DVORAK HF, 1995, AM J PATHOL, V146, P1029
[7]   The biology of VEGF and its receptors [J].
Ferrara, N ;
Gerber, HP ;
LeCouter, J .
NATURE MEDICINE, 2003, 9 (06) :669-676
[8]   Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1 [J].
Gale, NW ;
Thurston, G ;
Hackett, SF ;
Renard, R ;
Wang, Q ;
McClain, J ;
Martin, C ;
Witte, C ;
Witte, MH ;
Jackson, D ;
Suri, C ;
Campochiaro, PA ;
Wiegand, SJ ;
Yancopoulos, GD .
DEVELOPMENTAL CELL, 2002, 3 (03) :411-423
[9]   Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development [J].
Gale, NW ;
Yancopoulos, GD .
GENES & DEVELOPMENT, 1999, 13 (09) :1055-1066
[10]   Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions [J].
Gamble, JR ;
Drew, J ;
Trezise, L ;
Underwood, A ;
Parsons, M ;
Kasminkas, L ;
Rudge, J ;
Yancopoulos, G ;
Vadas, MA .
CIRCULATION RESEARCH, 2000, 87 (07) :603-607